Harvey Capital Management Upped By $1.06 Million Its Portola Pharmaceuticals (PTLA) Position; MYND ANALYTICS (MYAN) Sellers Increased By 21.43% Their Shorts

July 17, 2017 - By Marie Mckinney

Harvey Capital Management Inc increased Portola Pharmaceuticals Inc (PTLA) stake by 26.12% reported in 2016Q4 SEC filing. Harvey Capital Management Inc acquired 48,100 shares as Portola Pharmaceuticals Inc (PTLA)’s stock rose 22.73%. The Harvey Capital Management Inc holds 232,230 shares with $5.21 million value, up from 184,130 last quarter. Portola Pharmaceuticals Inc now has $3.52B valuation. The stock decreased 1.16% or $0.73 on July 14, reaching $62.42. About shares traded. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has risen 51.17% since July 17, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

MYND ANALYTICS INCORPORATED (NASDAQ:MYAN) had an increase of 21.43% in short interest. MYAN’s SI was 1,700 shares in July as released by FINRA. Its up 21.43% from 1,400 shares previously. With 1,300 avg volume, 1 days are for MYND ANALYTICS INCORPORATED (NASDAQ:MYAN)’s short sellers to cover MYAN’s short positions. The stock decreased 1.59% or $0.07 on July 14, reaching $4.33. About shares traded. MYnd Analytics Inc (NASDAQ:MYND) has 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

MYnd Analytics, Inc., formerly CNS Response, Inc., is a predictive analytics company. The company has market cap of $7.25 million. The Firm has developed a decision support tool to help physicians reduce trial and error treatment in mental health, and provide personalized care to patients. It currently has negative earnings. The Firm provides objective clinical decision support to mental healthcare providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder and other non-psychotic disorders.

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Portola Pharmaceuticals had 19 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Neutral” rating by Goldman Sachs on Monday, March 28. The rating was maintained by Oppenheimer on Monday, June 26 with “Buy”. Citigroup maintained it with “Buy” rating and $36 target in Friday, May 27 report. On Monday, June 26 the stock rating was maintained by Cowen & Co with “Buy”. The firm has “Outperform” rating given on Tuesday, December 27 by Credit Suisse. On Monday, March 28 the stock rating was maintained by Credit Suisse with “Outperform”. On Wednesday, August 10 the stock rating was maintained by Citigroup with “Buy”. The firm earned “Neutral” rating on Friday, August 19 by Citigroup. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Buy” rating by Goldman Sachs on Friday, December 18. The firm has “Buy” rating given on Monday, June 26 by Citigroup.

Since March 1, 2017, it had 1 buying transaction, and 6 selling transactions for $58.31 million activity. $40,556 worth of Portola Pharmaceuticals Inc (NASDAQ:PTLA) was sold by Fu Tao. BIRD JEFFREY W bought 119,442 shares worth $3.80 million. Shares for $937,500 were sold by HOMCY CHARLES J. Maxwell (Mauritius) Pte Ltd sold 1.70M shares worth $58.48M. Lis William also sold $243,405 worth of Portola Pharmaceuticals Inc (NASDAQ:PTLA) shares. Dier Mardi sold $409,605 worth of stock or 10,235 shares.

Harvey Capital Management Inc decreased Cvs Caremark Corp (NYSE:CVS) stake by 5,900 shares to 8,100 valued at $639,000 in 2016Q4. It also reduced General Electric Co (NYSE:GE) stake by 75,000 shares and now owns 20,000 shares. The Walt Disney Co (NYSE:DIS) was reduced too.

Investors sentiment decreased to 1.05 in Q4 2016. Its down 0.04, from 1.09 in 2016Q3. It dived, as 17 investors sold PTLA shares while 42 reduced holdings. 17 funds opened positions while 45 raised stakes. 48.44 million shares or 1.23% less from 49.04 million shares in 2016Q3 were reported. Vanguard Gru reported 4.42M shares. Hall Laurie J Trustee accumulated 190 shares or 0% of the stock. Nicholas Prtn Limited Partnership holds 0.04% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 24,013 shares. Moreover, Millennium Mgmt Limited Liability Co has 0.05% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 1.13 million shares. Parametric Associates Lc, Washington-based fund reported 21,369 shares. Allianz Asset Mgmt Ag holds 0% or 16,620 shares. Goldman Sachs Grp Incorporated reported 166,806 shares. Joel Isaacson Ltd Llc has invested 0.01% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Focused Wealth Mgmt Inc holds 125 shares. Sectoral Asset Management has invested 3.53% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Bnp Paribas Arbitrage reported 0% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Us Financial Bank De holds 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 41,000 shares. Sphera Funds Management owns 100,000 shares. 101,491 were reported by California State Teachers Retirement Systems. Voya Mngmt Lc invested in 0.02% or 421,559 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: